ArticlePLoS pathogens2025
The PP2A-2 holoenzyme orchestrates daughter cell emergence during cytokinesis in Toxoplasma gondii.
Article in PLoS pathogens, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Toxoplasma gondii is a significant pathogen in both humans and animals, with disease progression driven by the rapid proliferation of its tachyzoite stage. In this study, we identify the PP2A-2 holoenzyme as a key regulator of daughter cell emergence during parasite division. This holoenzyme, likely composed of the regulatory subunit TgPR48 (PP2A-B2), the catalytic subunit PP2A-C2, and the scaffolding subunit PP2A-A2, is essential for proper cytokinesis. Disruption of any single component severely impairs daughter cell separation and emergence. Phosphoproteomic analysis following PP2A-C2 depletion revealed numerous differentially phosphorylated proteins. Among these, DCS1 and DCS2 were prioritized as potential effectors. While phosphomimetic and non-phosphorylatable mutations in DCS1 and DCS2 did not significantly impair their function, depletion of either protein disrupted TgPR48 localization. Interestingly, TgPR48 overexpression partially rescued the phenotypes associated with DCS2 loss, but not DCS1, indicating divergence in their downstream pathways and implicating additional, yet unidentified, substrates. These findings establish PP2A-2-mediated dephosphorylation as a central mechanism in regulating tachyzoite cytokinesis and highlight a promising regulatory axis for therapeutic intervention against T. gondii.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.